Premium Respiratory Care Solution for Asthma and COPD Patients
Vilanterol 25 mcg + Fluticasone Furoate 100 mcg + Glycopyrronium 50 mcg Inhalation Powder is a modern triple-combination inhalation therapy developed for long-term management of chronic respiratory diseases such as asthma and Chronic Obstructive Pulmonary Disease (COPD). This advanced formulation combines a long-acting bronchodilator, an inhaled corticosteroid, and a long-acting muscarinic antagonist to provide comprehensive airway control and improved breathing capacity.
Composition
Each Inhalation Dose Contains:
Vilanterol – 25 mcg
Fluticasone Furoate – 100 mcg
Glycopyrronium – 50 mcg
Therapeutic Category
Anti-Asthmatic Medication
COPD Management Therapy
Triple Combination Inhalation Therapy
Long-Acting Bronchodilator
Inhaled Corticosteroid Treatment
Mechanism of Action
Vilanterol Acts as a Long-Acting Beta2 Agonist (LABA) that relaxes airway muscles and helps keep air passages open for easier breathing.
Fluticasone Furoate A potent corticosteroid that reduces inflammation, swelling, and irritation within the lungs.
Glycopyrronium A Long-Acting Muscarinic Antagonist (LAMA) that prevents airway narrowing and improves lung function.
Treatment Applications
This inhalation powder is prescribed for:
Moderate to Severe Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Chronic Bronchitis
Emphysema
Persistent Respiratory Symptoms
Prevention of Asthma Exacerbations
Long-Term COPD Maintenance Therapy
Breathlessness and Wheezing Management
Key Benefits
✔ Triple-action respiratory control
✔ Improved lung function
✔ Reduced frequency of COPD flare-ups
✔ Better symptom management
✔ Once-daily administration
✔ Enhanced quality of life for chronic respiratory patients
✔ Reduced inflammation and airway obstruction
Storage Instructions
Store below 30°C.
Protect from moisture and direct sunlight.
Keep inhaler sealed until use.
Keep out of reach of children.
Do not freeze.
Use according to physician instructions.
South Africa Respiratory Market Focus
South Africa continues to witness increasing demand for advanced asthma and COPD therapies due to growing respiratory health concerns, urban pollution, smoking-related diseases, and occupational lung disorders.
High-Demand Provinces for Asthma & COPD Products
Gauteng
Major healthcare hub including Johannesburg and Pretoria with strong demand for respiratory medications.
Western Cape
Cape Town and surrounding regions show significant demand for chronic respiratory disease management.
KwaZulu-Natal
Large patient population requiring long-term asthma and COPD therapies.
Eastern Cape
Increasing diagnosis and treatment of chronic respiratory disorders.
Free State
Growing utilization of advanced inhalation therapies in hospitals and clinics.
Mpumalanga
Demand driven by industrial and mining-related respiratory conditions.
Limpopo
Expanding healthcare infrastructure supporting respiratory treatment access.
Healthcare Supply Opportunities
Hospitals
Pulmonology Clinics
Respiratory Care Centers
Community Pharmacies
Medical Distributors
Government Tenders
Private Healthcare Networks
Global Supply from India
Cordium Pharmaceuticals offers reliable pharmaceutical export solutions for respiratory care products with support for:
Product Documentation
Regulatory Assistance
Bulk Supply Programs
Hospital Procurement
Pharmacy Distribution
International Logistics Support
Contact for Export Enquiries
Cordium Pharmaceuticals Pvt. Ltd.
WhatsApp: +91-9405117673
Email: info@cordiumpharma.com
Serving healthcare buyers, distributors, pharmacies, hospitals, and respiratory specialists worldwide.
Vilanterol 25 mcg + Fluticasone Furoate 100 mcg + Glycopyrronium 50 mcg Inhalation Powder is a modern triple-combination inhalation therapy developed for long-term management of chronic respiratory diseases such as asthma and Chronic Obstructive Pulmonary Disease (COPD). This advanced formulation combines a long-acting bronchodilator, an inhaled corticosteroid, and a long-acting muscarinic antagonist to provide comprehensive airway control and improved breathing capacity.
Composition
Each Inhalation Dose Contains:
Vilanterol – 25 mcg
Fluticasone Furoate – 100 mcg
Glycopyrronium – 50 mcg
Therapeutic Category
Anti-Asthmatic Medication
COPD Management Therapy
Triple Combination Inhalation Therapy
Long-Acting Bronchodilator
Inhaled Corticosteroid Treatment
Mechanism of Action
Vilanterol Acts as a Long-Acting Beta2 Agonist (LABA) that relaxes airway muscles and helps keep air passages open for easier breathing.
Fluticasone Furoate A potent corticosteroid that reduces inflammation, swelling, and irritation within the lungs.
Glycopyrronium A Long-Acting Muscarinic Antagonist (LAMA) that prevents airway narrowing and improves lung function.
Treatment Applications
This inhalation powder is prescribed for:
Moderate to Severe Asthma
Chronic Obstructive Pulmonary Disease (COPD)
Chronic Bronchitis
Emphysema
Persistent Respiratory Symptoms
Prevention of Asthma Exacerbations
Long-Term COPD Maintenance Therapy
Breathlessness and Wheezing Management
Key Benefits
✔ Triple-action respiratory control
✔ Improved lung function
✔ Reduced frequency of COPD flare-ups
✔ Better symptom management
✔ Once-daily administration
✔ Enhanced quality of life for chronic respiratory patients
✔ Reduced inflammation and airway obstruction
Storage Instructions
Store below 30°C.
Protect from moisture and direct sunlight.
Keep inhaler sealed until use.
Keep out of reach of children.
Do not freeze.
Use according to physician instructions.
South Africa Respiratory Market Focus
South Africa continues to witness increasing demand for advanced asthma and COPD therapies due to growing respiratory health concerns, urban pollution, smoking-related diseases, and occupational lung disorders.
High-Demand Provinces for Asthma & COPD Products
Gauteng
Major healthcare hub including Johannesburg and Pretoria with strong demand for respiratory medications.
Western Cape
Cape Town and surrounding regions show significant demand for chronic respiratory disease management.
KwaZulu-Natal
Large patient population requiring long-term asthma and COPD therapies.
Eastern Cape
Increasing diagnosis and treatment of chronic respiratory disorders.
Free State
Growing utilization of advanced inhalation therapies in hospitals and clinics.
Mpumalanga
Demand driven by industrial and mining-related respiratory conditions.
Limpopo
Expanding healthcare infrastructure supporting respiratory treatment access.
Healthcare Supply Opportunities
Hospitals
Pulmonology Clinics
Respiratory Care Centers
Community Pharmacies
Medical Distributors
Government Tenders
Private Healthcare Networks
Global Supply from India
Cordium Pharmaceuticals offers reliable pharmaceutical export solutions for respiratory care products with support for:
Product Documentation
Regulatory Assistance
Bulk Supply Programs
Hospital Procurement
Pharmacy Distribution
International Logistics Support
Contact for Export Enquiries
Cordium Pharmaceuticals Pvt. Ltd.
WhatsApp: +91-9405117673
Email: info@cordiumpharma.com
Serving healthcare buyers, distributors, pharmacies, hospitals, and respiratory specialists worldwide.
Keywords
